{"filings":[{"id":2226557,"accession_number":"0001104659-26-095491","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-08-13T12:05:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q2 net income $160.7M; bota-vec acquired, $400M Oberland deal, BTD for AAV2-hAQP1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net income $160.7M ($1.76 basic EPS) vs net loss $38.8M in Q2 2025; revenue from services and licenses surged.","Completed $25M acquisition of bota-vec (XLRP) from J&J; $100M equity financing; up to $400M Oberland investment with $375M non-dilutive.","FDA granted Breakthrough Therapy Designation for AAV2-hAQP1; Phase 2 AQUAx2 enrollment completed; 3-year data positive.","Lilly collaboration: $75M upfront, up to $400M milestones for medu-vec and gene therapy tech; also $95M due from Hologen.","Cash $145.4M at June 30, 2026; expects runway into H2 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1481076,"accession_number":"0001104659-26-080949","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-07-07T11:42:01+00:00","items":["1.01","1.02","2.03","3.02","7.01","9.01"],"status":"ready","headline":"MeiraGTx secures up to $400M from Oberland Capital in royalty and equity deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial $135M funded: $125M in exchange for low single-digit capped royalties on three products, plus $10M equity investment at $10.52/share.","Additional tranches: $50M upon AAV2-hAQP1 Phase 2 data, $50M upon bota-vec approval, $50M upon AAV2-hAQP1 approval, up to $100M mutual.","Company redeemed all outstanding notes under Perceptive NPA, terminating that agreement with no early termination penalties.","Royalty payments capped at a multiple of amounts funded; flexible change-of-control provisions allow buyback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1057756,"accession_number":"0001104659-26-074085","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-06-15T20:37:50+00:00","items":["5.07"],"status":"ready","headline":"MeiraGTx shareholders elect three Class II directors and ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held June 11, 2026; 75,326,022 shares (81.4%) represented.","Ellen Hukkelhoven, Nicole Seligman, Debra Yu elected as Class II directors with >54M votes each.","Ernst & Young LLP ratified as independent auditor for FY 2026 with 73,933,288 votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77962,"accession_number":"0001104659-26-060726","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-05-14T12:06:12+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q1 net loss $46.3M; reacquires bota-vec from J&J; raises $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to ordinary shareholders was $46.3M ($0.57 per share) for Q1 2026, vs $40.0M ($0.51) in Q1 2025.","Cash and cash equivalents were $71.5M at March 31, 2026; subsequent $100M equity offering and $25M upfront payment to J&J for bota-vec.","Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; positive 3-year data from Phase 1 AQUAx study.","Appointed Penny Fleck as Chief Development Officer; Stuart Naylor as Chief Scientific Officer, Ophthalmology.","Reacquired full rights to bota-vec for XLRP from J&J with $25M upfront plus milestones and mid-teens royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95078,"accession_number":"0001104659-26-048196","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MeiraGTx closes initial $200M Hologen collaboration; Hologen to own 70% of neuro JV","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed initial closing of strategic collaboration with Hologen on April 20, 2026; Hologen provided $200M upfront cash payment.","Hologen to fund remaining portion of upfront via post-completion share purchases, ultimately owning 70% of HNAI and minority stake in MeiraGTx Manufacturing.","Collaboration covers AAV-GAD for Parkinson's disease, AAV-BDNF for genetic obesity disorders, and proprietary CNS delivery device.","MeiraGTx Neuro UK retains 30% of HNAI; Hologen gets exclusive option to buy up to 40% of MeiraGTx Manufacturing shares within 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95077,"accession_number":"0001104659-26-044462","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MeiraGTx prices $100M public offering of 11.1M shares at $9.00 each; net proceeds ~$93.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["11,111,111 ordinary shares at $9.00/sh; net proceeds ~$93.3M after underwriting discounts and expenses.","Closing expected April 17, 2026; proceeds for general corporate purposes, working capital, capital expenditures.","Cash plus net proceeds expected to fund operating expenses and capital needs into H2 2028, including potential launches of bota-vec and AAV-hAQP1 if approved.","Underwriting agreement with BofA Securities, Inc. and Goldman Sachs & Co. LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95076,"accession_number":"0001104659-26-044028","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","1.02","2.01","7.01","8.01","9.01"],"status":"ready","headline":"MeiraGTx acquires bota-vec gene therapy from Janssen for XLRP treatment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["MeiraGTx paid $25M upfront to Janssen for bota-vec, with a potential $50M milestone upon US approval and $250M sales threshold.","Phase 3 LUMEOS trial showed 40% of treated patients improved in ≥2 endpoints vs 0% in control.","MeiraGTx intends to file BLA and MAA in US, EU, and Japan for bota-vec, targeting potential launch in 2027.","JJDC, Johnson & Johnson investment arm, owns >5% of MeiraGTx shares and agreed to 12-month lock-up.","Estimated >20,000 XLRP patients in US and EU, with potential peak market of $1.7B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95075,"accession_number":"0001104659-26-044025","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MeiraGTx reports positive 3-year Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["62% of patients had ≥10-point XQ improvement at 36 months; average 17-point improvement maintained from 12 months.","Unstimulated saliva flow normalized to average 0.36 mL/min at 12 months, maintained at 0.34 mL/min at 36 months.","No dose-limiting toxicity or treatment-related serious adverse events; well tolerated at all doses.","Company estimates peak global revenue potential of $3.7B, U.S. peak of $2.0B, targeting ~165,000 U.S. patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107888,"accession_number":"0001104659-26-034904","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"MeiraGTx: FDA Breakthrough for xerostomia, FY2025 net loss $114.2M, $200M Hologen JV","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; RMAT also granted.","Strategic JV with Hologen: $200M upfront, $230M additional funding for AAV-GAD, MeiraGTx holds 30% ownership.","Collaboration with Lilly: $75M upfront, >$400M milestones for AAV-AIPL1 and other ocular assets.","FY2025 net loss $114.2M ($1.42/share) vs $147.8M ($2.12/share) in FY2024; cash $68.2M.","Debt amendment: maturity extended to May 2027, $25M redemption by June 30, 2026, warrant price reduced to $8.00."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107887,"accession_number":"0001104659-26-000068","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MeiraGTx repurchases 2.3M shares from Perceptive Master Fund for $18.2M at $7.91 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bought 2,300,000 ordinary shares from Perceptive Life Sciences Master Fund at VWAP of $7.91, aggregate $18.2M.","Perceptive Master Fund and affiliates hold >10% of outstanding shares and a $75M note with the company.","Selling shareholder subject to 12-month lock-up on remaining Perceptive shares, with limited exceptions.","Perceptive Credit Holdings III consented to the repurchase under the Notes Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124302,"accession_number":"0001104659-25-110883","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q3 net loss $50.5M; enters ophthalmology collaboration with Lilly for $75M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration with Lilly: upfront $75M, eligible for >$400M milestones and tiered royalties on ocular programs.","Cash $14.8M at Sept 30; with Lilly $75M and Hologen $150M expected, runway into H2 2027 covers $75M debt due Aug 2026.","Net loss $50.5M ($0.62/share) vs $39.3M ($0.55) YoY; service revenue fell to $0.4M from $10.9M as J&J PPQ substantially completed.","AAV-hAQP1 Phase 2 enrollment target end of 2025; positive data could support BLA filing early 2027.","AAV-GAD Phase 3 for Parkinson's expected to initiate in coming months; RMAT designation granted."],"consensus_eps_estimate":-0.4998,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":6027000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124301,"accession_number":"0001104659-25-108804","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"MeiraGTx licenses AAV-AIPL1 and gene therapy tools to Lilly for $75M upfront, up to $400M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $75M; eligible for over $400M in total milestones, including up to $135M near-term.","Lilly gets exclusive worldwide rights to AAV-AIPL1 for LCA4, which restored vision in 11 blind children.","Also licenses proprietary intravitreal capsids, promoters (AI-generated), and riboswitch gene-editing rights.","MeiraGTx eligible for tiered royalties; retains ownership of certain technology improvements; Lilly funds all R&D and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140973,"accession_number":"0001558370-25-011478","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q2 net loss narrows to $38.8M; FDA alignment on RIX pivotal study, RMAT for Parkinson's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.8M ($0.48/sh) vs $48.6M ($0.76/sh) in Q2 2024; cash $32.2M at June 30, 2025.","FDA aligns on AAV-hAQP1 Phase 2 AQUAx2 as potentially pivotal for BLA in radiation-induced xerostomia; enrollment target Q4 2025, data late 2026.","FDA grants RMAT designation for AAV-GAD in Parkinson's; clean GCP inspection; Phase 3 study planned in 2025.","Received $23M of $200M from Hologen collaboration; forming JV Hologen Neuro AI with up to $230M funding for AAV-GAD development.","Preparing MAA in UK and BLA in US for AAV-AIPL1 in LCA4; Lancet publication shows all 11 treated children now able to see."],"consensus_eps_estimate":-0.4769,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":5617000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158743,"accession_number":"0001558370-25-008870","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"MeiraGTx receives UK FDI clearances for Hologen deal; closing expected July 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["UK foreign direct investment clearances obtained for proposed transactions with Hologen Limited.","Transactions originally entered into on March 9, 2025.","Closing now expected in July 2025.","No financial terms disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158742,"accession_number":"0001558370-25-008676","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MeiraGTx annual meeting elects director, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director Thomas E. Shenk elected with 40.3M votes for, 9.1M withheld, 9.9M broker non-votes.","Ernst & Young LLP ratified as auditor for FY2025 (45.4M for, 13.9M against, 34K abstain).","Annual meeting held June 12, 2025; 74.2% of shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158741,"accession_number":"0001558370-25-007497","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q1 net loss $40.0M; announces $200M Hologen AI collaboration, RMAT for AAV-GAD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $40.0M ($0.51/share) vs $20.4M ($0.32) YoY; revenue $1.9M; cash $66.5M.","Hologen AI collaboration: $200M upfront to MeiraGTx; joint venture with $230M committed capital.","FDA granted RMAT designation for AAV-GAD Parkinson's; Phase 3 study planned H2 2025.","AAV-AIPL1 data in Lancet: 11/11 children with LCA4 responded; expedited approval discussions underway.","Bota-vec Phase 3 XLRP trial primary endpoint not met; secondary endpoints showed benefit across vision domains."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":1926000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158740,"accession_number":"0001558370-25-007074","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA grants RMAT designation to MeiraGTx's AAV-GAD for Parkinson's disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["RMAT designation based on data from three clinical studies (Phase 1 n=12, Phase 2 n=45, dose-ranging n=14).","AAV-GAD showed significant benefit on UPDRS Part 3 motor endpoint in double-blind sham-controlled trials.","Hologen AI analysis indicated disease-modifying brain circuitry changes, first in sham-controlled Parkinson's study.","RMAT includes Fast Track and Breakthrough Therapy benefits, rolling review, and potential Priority Review for BLA.","MeiraGTx plans to work closely with FDA to advance this one-time gene therapy for Parkinson's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158739,"accession_number":"0001558370-25-004490","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"MeiraGTx enters 7yr7mo lease for 14,235 sq ft NYC lab; terminates prior sublease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New lease with ARE-East River Science Park for lab/office space at $111/sq ft/yr, 3% annual escalations.","Landlord contributes $50/sq ft ($712K) toward tenant improvements; rent abated first 4 months plus a period in year 2.","Initial term ~7yr7mo with a 5-year extension option; expected commencement between July and August 2025.","Existing sublease with ImClone Systems terminated early, from Oct 2026 to ~Aug 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177139,"accession_number":"0001558370-25-002859","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"MeiraGTx enters collaboration with Hologen AI: $200M upfront, $230M JV funding for AAV-GAD","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received $200M upfront cash from Hologen; forming JV Hologen Neuro AI Ltd.","Hologen commits up to $230M additional capital to JV to fund AAV-GAD Parkinson's development.","MeiraGTx retains 30% ownership in JV, leads clinical development and manufacturing.","Hologen takes minority stake in MeiraGTx's manufacturing subsidiary; AI optimization.","Closing expected Q2 2025, subject to UK FDI regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193920,"accession_number":"0001558370-24-016089","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MeiraGTx granted FDA RMAT designation for AAV2-hAQP1 in Grade 2/3 radiation-induced xerostomia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA's RMAT designation includes Fast Track, Breakthrough Therapy benefits and potential Priority Review and accelerated approval.","Phase 1 AQUAx trial showed significant patient-reported outcomes and saliva production improvements with no serious adverse events.","Phase 2 AQUAx2 double-blind, placebo-controlled trial is enrolling; FDA agreed Phase 2 may serve as pivotal trial for BLA filing.","AAV2-hAQP1 previously received FDA Orphan Drug Designation for this indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193919,"accession_number":"0001558370-24-015441","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx secures MHRA pathway for AAV-AIPL1 approval without further studies; Q3 net loss $39.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["AAV-AIPL1 MAA under exceptional circumstances agreed with MHRA; no further clinical studies required for UK approval.","11 blind children treated with AAV-AIPL1 all gained vision within 4+ weeks; FDA discussions initiated for similar US pathway.","AAV-GAD bridging study met safety endpoint; 18-point improvement in UPDRS Part 3 'off' score (p=0.03) at Week 26.","Three FDA Rare Pediatric Disease Designations awarded for AIPL1, BBS10, and RDH12 programs.","Cash $122.9M + $3.3M receivables; net loss $39.3M ($0.55 per share) vs $44.3M ($0.74) YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":11889000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193918,"accession_number":"0001558370-24-013273","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MeiraGTx reports positive Phase 2 data for AAV-GAD in Parkinson's; 18-point UPDRS improvement in high-dose group","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AAV-GAD met primary safety endpoint; no SAEs related to treatment in 14-patient bridging study.","High-dose group showed 18-point average improvement in UPDRS Part 3 off-medication (p=0.03); sham and low-dose showed no significant change.","PDQ-39 quality-of-life score improved by 8 points (p=0.02) in high-dose and 6 points (p=0.04) in low-dose groups.","100% of high-dose participants reported PDQ-39 improvement vs 60% low-dose and 25% sham.","Company plans to advance AAV-GAD into Phase 3 trial globally; total of 58 patients treated across program with no related SAEs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210245,"accession_number":"0001104659-24-089011","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MeiraGTx closes public offering of 12.5M shares at $4.00, netting $48.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 12,500,000 ordinary shares at $4.00/share completed August 13, 2024; net proceeds ~$48.3M.","Proceeds intended for general corporate purposes, including working capital and capital expenditures.","Company expects existing cash plus net proceeds and near-term J&J milestones to fund operations into Q2 2026.","J&J Asset Purchase Agreement provides up to $285M in milestone payments upon first commercial sale of bota-vec for XLRP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210244,"accession_number":"0001558370-24-011797","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx reports Q2 net loss of $48.6M and $50M offering led by Sanofi","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $48.6M ($0.76/share) vs $29.6M ($0.53) in Q2 2023; service revenue $0.3M, no license revenue.","Offering of 12.5M shares at $4.00 each for $50M gross proceeds; led by Sanofi ($30M) with Perceptive Advisors.","Cash and equivalents $100.0M as of June 30, 2024; believes funded into Q2 2026 with $285M potential J&J milestones.","Phase 2 AQUAx2 for xerostomia enrolling; FDA aligned on pivotal trial design. AAV-GAD for Parkinson's results expected Q4 2024.","UK ILAP designation for AAV-AIPL1 in LCA4; all 11 treated blind children gained visual acuity. Riboswitch platform data later 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228537,"accession_number":"0001558370-24-009041","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MeiraGTx 2024 AGM results: directors elected, say-on-pay approved, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class III directors elected: Forbes (99.8% cast, 49.6M for), Harris (99.5%), Mendoza (99.7%).","Advisory say-on-pay approved with 49.3M for (99.2% of votes cast excluding broker non-votes).","Shareholders selected 3-year frequency for future advisory say-on-pay votes (27.2M for 3 years).","Ratification of Ernst & Young as FY2024 auditor passed with 55.3M for (99.8% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228536,"accession_number":"0001558370-24-007476","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q1 net loss narrows to $20.4M; receives $50M milestone from Janssen","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to shareholders $20.4M ($0.32 per share) vs $30.4M ($0.62) in Q1 2023.","Cash and cash equivalents $119.2M at March 31; $138.9M after April collections; runway into Q1 2026.","Received $50M milestone from Janssen for Phase 3 LUMEOS extension study initiation for bota-vec in XLRP.","Phase 1 AQUAx data showed 112.8% increase in unstimulated saliva flow at 12 months; pivotal Phase 2 enrolling.","Completed dosing in Phase 1 bridging study for AAV-GAD Parkinson's gene therapy; Phase 3 design discussions in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":697000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228535,"accession_number":"0001558370-24-005201","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K/A","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MeiraGTx amends prior 8-K to disclose Dr. Debra Yu's committee appointments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Debra Yu, M.D., joined the Board on April 25, 2022; this amendment adds committee assignments.","Effective April 15, 2024, Dr. Yu appointed to both Compensation Committee and Science & Technology Committee.","Amendment relates solely to disclosure of committee appointments; no other changes to prior filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247198,"accession_number":"0001558370-24-003175","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx reports FY2023 net loss of $84M, down 35% YoY; Janssen deal yields $50M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $84.0M ($1.49/share) vs $129.6M ($2.87) in 2022; license revenue $14.0M.","Janssen asset purchase for bota-vec (XLRP) up to $415M; $65M upfront + $50M milestone in Feb 2024.","Sanofi invested $30M at $7.50/share; ROFN for riboswitch in CNS, I&I, metabolic disease.","FDA aligns Phase 2 AQUAx2 for xerostomia as pivotal; AAV-AIPL1 shows meaningful responses in 8 LCA4 children.","Cash $129.6M at Dec 31, 2023; expects funding into Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247197,"accession_number":"0001558370-24-001020","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MeiraGTx receives $50M milestone from Janssen for bota-vec Phase 3 extension study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$50M milestone triggered by initiation of LUMEOS extension study for bota-vec (XLRP gene therapy).","Additional $15M in near-term milestone payments expected later in 2024 from Janssen.","Up to $285M further payments on first U.S./EU commercial sales and manufacturing tech transfer.","Commercial supply agreement with J&J for bota-vec manufacturing expected to generate ongoing revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264639,"accession_number":"0001558370-23-019944","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["1.01","1.02","2.01","2.03","7.01","9.01"],"status":"ready","headline":"MeiraGTx sells bota-vec rights to J&J's Janssen for up to $415M; $130M upfront/near-term","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $65M at signing; additional $50M expected Q1 2024 and $15M later, totaling $130M near-term.","Up to $285M in milestones tied to first U.S./EU commercial sales and manufacturing tech transfer.","MeiraGTx enters commercial supply agreement with Janssen for bota-vec manufacturing.","Cash runway extended to mid-2026, including $30M Sanofi investment from October 2023.","Prior Collaboration, Option and License Agreement with Janssen terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264638,"accession_number":"0001558370-23-018914","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx reports Q3 net loss $44.3M; Sanofi invests $30M at $7.50/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sanofi purchased $30M of ordinary shares at $7.50/share; ROFN for Riboswitch platform on CNS, I&I, metabolic targets including GLP-1 and Xerostomia.","Q3 net loss $44.3M ($0.74 per share) vs $37.3M ($0.83) prior year; license revenue $5.1M.","R&D expenses rose 65% to $27.9M driven by manufacturing costs and Janssen collaboration changes.","Cash $64.4M plus $22M Janssen receivables and $30M Sanofi investment; runway into mid-2025.","Phase 3 XLRP trial fully enrolled with IND transferred to Janssen; Phase 2 Xerostomia and Parkinson's studies ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":11977000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264637,"accession_number":"0001558370-23-016977","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"MeiraGTx announces $30M Sanofi investment at $7.50/share; exploring additional strategic transactions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sanofi subsidiary purchased 4M ordinary shares at $7.50 each for gross proceeds of $30M; shares subject to 18-month lock-up and standstill for 24 months.","Sanofi receives right of first negotiation for Riboswitch gene regulation tech in I&I, CNS, metabolic targets and MeiraGTx's Phase 2 Xerostomia program.","MeiraGTx has been approached by multiple parties with strategic interest in different assets; engaged Evercore and Wachtell Lipton to evaluate potential transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281875,"accession_number":"0001558370-23-014412","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"MeiraGTx Q2 net loss $29.6M; Phase 3 XLRP trial enrollment surpassed; secures $25M note amendment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 net loss $29.6M ($0.53/share) vs $34.0M ($0.76) YoY; license revenue $3.5M (down from $10.8M).","Cash $92.8M at June 30, 2023; with Janssen receivables, runway into Q2 2025.","Phase 3 LUMEOS trial of bota-vec for XLRP enrollment target surpassed; BLA submission expected in 2024.","Consent and Amendment allows MeiraGTx to request $25M additional notes at its discretion (previously Perceptive's).","Shannon manufacturing facility received first commercial MIA authorization for gene therapy QC testing in Ireland."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":6874000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300869,"accession_number":"0001558370-23-010991","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MeiraGTx annual meeting results: all director nominees elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Turnout of 77.3% (37,669,017 shares) at annual meeting on June 8, 2023.","Class II directors elected: Hukkelhoven (31.5M for), Seligman (31.6M for), Yu (32.0M for).","Ratification of Ernst & Young as auditor passed with 37.1M votes for, 0.5M against.","No broker non-votes on auditor ratification; 5.5M broker non-votes on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300868,"accession_number":"0001558370-23-009270","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q1 net loss $30.4M; raises $60M PIPE; BLA on track for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.4M ($0.62/share) vs $31.0M ($0.70) in Q1 2022; cash $68.8M at March 31, 2023.","Raised ~$60M in May 2023 PIPE led by top holders Perceptive, Adage, Prosight, 683 Capital.","BLA submission for bota-vec (XLRP) remains on track for 2024; Phase 3 LUMEOS enrollment ongoing.","AAV-hAQP1 Phase 1 12-month data for xerostomia to be presented Q2 2023; Phase 2 to start Q2 2023.","License revenue $3.3M (down from $5.6M); R&D $22.3M (down from $23.1M); G&A $12.8M (up from $11.3M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":3334000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300867,"accession_number":"0001558370-23-008883","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"MeiraGTx raises $62M in private placement at $5.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 10,773,913 ordinary shares at $5.75/share for gross proceeds of ~$62M; closed May 5, 2023.","Shares sold to accredited investors under Section 4(a)(2); registration rights agreement requires filing registration statement by August 3, 2023.","Investor Perceptive Life Sciences Master Fund (owns >10% of shares) participated; board member Ellen Hukkelhoven is Head of Biotech at Perceptive Advisors.","No specific use of proceeds disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300866,"accession_number":"0001558370-23-006872","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Arnold J. Levine resigns from MeiraGTx board for health reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Arnold J. Levine, Ph.D. resigned from the Board effective April 21, 2023.","Resignation is for personal health-related reasons.","Dr. Levine will continue to serve on the Company's Scientific Advisory Board.","No replacement announced; Board thanks him for his service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320772,"accession_number":"0001558370-23-003644","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx reports 2022 net loss $129.6M; pipeline advances toward 2024 BLA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $129.6M ($2.87/share) vs $79.6M in 2021; revenue $15.9M (down from $37.7M on lower milestone payments).","Cash and equivalents $115.5M plus $21M Janssen receivables; expected runway into Q4 2024.","Phase 3 Lumeos trial for botaretigene sparoparvovec (XLRP) enrolling; BLA submission on track for 2024.","AAV-hAQP1 for xerostomia showed 75% symptom improvement; Phase 2 planned Q2 2023.","AAV-GAD for Parkinson's dosing patients; enrollment completion anticipated Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320771,"accession_number":"0001558370-23-003424","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"MeiraGTx discloses no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company does not hold cash deposits or securities with Silicon Valley Bank.","Company does not have any business relationship with Silicon Valley Bank.","Disclosure filed on March 10, 2023, amid SVB collapse concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338902,"accession_number":"0001558370-22-017297","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["1.01","2.02","3.02","9.01"],"status":"ready","headline":"MeiraGTx reports Q3 2022 net loss $37.3M; receives $25M investment from JJDC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $37.3M ($0.83 per share) vs $25.9M ($0.59) in Q3 2021.","License revenue of $4.8M, down from $6.9M YoY on lower amortization from Janssen.","Cash and equivalents $114.7M at Sept 30 plus $23.7M receivables from Janssen; funded into Q4 2024.","Received $25M private placement from JJDC at $6.68/share (3.74M shares) for preclinical and manufacturing.","Dosing Phase 1 AAV-GAD for Parkinson's; XLRP Phase 3 LUMEOS on track for BLA in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":21208000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356274,"accession_number":"0001558370-22-013188","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q2 net loss $34M; positive XLRP gene therapy data; extends cash runway to Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.0M ($0.76/share) vs $20.1M ($0.46) in Q2 2021; license revenue up to $10.8M.","Positive Phase 1/2 data for botaretigene sparoparvovec (AAV-RPGR) shows vision improvements in XLRP; Phase 3 Lumeos enrolling.","Secured up to $100M senior secured financing from Perceptive secured by manufacturing facilities; $75M received at close.","Cash and equivalents $72.1M at June 30 plus $15.9M Janssen receivable; cash runway to Q4 2024.","R&D expenses increased to $24.0M from $15.2M due to manufacturing and clinical costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":16392000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356273,"accession_number":"0001558370-22-012073","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"MeiraGTx secures up to $100M debt financing from Perceptive, collateralized by manufacturing facilities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$75M initial term loan from Perceptive Advisors, with option for additional $25M; interest at 10% + SOFR, maturity Aug 2026.","Collateralized by manufacturing facilities in London and Shannon, Ireland; no IP encumbered.","Warrants issued: 400k shares at $15 (92% premium) and 300k at $20 (156% premium), expire Aug 2027.","Proceeds to fund pipeline, extend cash runway to Q4 2024; Lumeos trial fully funded by Janssen.","Director Hukkelhoven is managing director at Perceptive; affiliates own >10% of MGTX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374654,"accession_number":"0001558370-22-010333","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Joel S. Marcus resigns from MeiraGTx board, effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joel S. Marcus resigned from Board of Directors and all committees, effective June 27, 2022.","Resignation is not due to any disagreement with company on operations, policies, or practices.","No successor or replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374653,"accession_number":"0001558370-22-009884","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MeiraGTx shareholders elect three Class I directors, ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["75.2% of outstanding ordinary shares were present or represented at June 7, 2022 AGM.","Martin Indyk: 28,934,284 FOR, 324,677 WITHHELD; Arnold Levine: 29,109,419 FOR, 149,542 WITHHELD; Thomas Shenk: 20,874,012 FOR, 8,384,949 WITHHELD.","Ratification of Ernst & Young as independent auditor for FY2022 passed with 20,713,225 FOR, 12,874,860 AGAINST, 6,322 ABSTAINED.","All three director nominees were elected and the auditor ratification was approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374652,"accession_number":"0001558370-22-008448","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q1 net loss widens to $0.70 per share; Phase 3 XLRP trial actively dosing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.0M ($0.70 per share) vs $23.6M ($0.54) in Q1 2021; R&D spend rose to $23.1M.","Cash and equivalents of $114M plus $13.1M Janssen receivable; runway into Q4 2023.","Phase 3 Lumeos trial of botaretigene sparoparvovec for XLRP actively dosing patients; BLA submission targeted in 2024.","Phase 1 AQUAx trial for radiation-induced xerostomia completed all cohorts; Phase 2 planned by year-end 2022.","IND for AAV-GAD in Parkinson's filed May 2022; riboswitch platform advancing to first-in-human studies by end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":5633000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374651,"accession_number":"0001558370-22-006046","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MeiraGTx appoints Debra Yu, MD to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Yu appointed effective April 25, 2022 as Class II director; term expires at 2023 annual meeting.","Recommended by largest shareholder Perceptive Advisors and senior management.","Currently President and Chief Strategy Officer of LianBio; over 30 years healthcare industry experience.","Previously held senior positions at Pfizer, Labrador Advisors, and two life science VC firms.","Eligible for compensation under Company's Non-Employee Director Compensation Program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393136,"accession_number":"0001558370-22-003224","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx reports 2021 net loss of $79.6M; cash $137.7M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $79.6M ($1.80/share) vs $58.0M ($1.54/share) in 2020; license revenue rose to $37.7M from $15.6M.","Cash and equivalents $137.7M at Dec 31, 2021; expects to fund operations through Q2 2023.","Phase 3 Lumeos trial for XLRP enrolling; received $30M milestone from Janssen.","Positive Phase 1 data for AAV-hAQP1 in xerostomia; Phase 2 start planned by end of 2022.","R&D expenses $67.1M vs $33.9M, driven by ophthalmology, neurology, and manufacturing programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411602,"accession_number":"0001558370-21-016575","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2021-12-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MeiraGTx reports positive Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia; 6/7 patients improved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6 of 7 participants achieved clinically meaningful improvement in xerostomia symptoms on two validated PRO measures.","One participant maintained maximal symptom improvement score of 7 at 24 months post-treatment.","AAV-hAQP1 well tolerated with no dose-limiting toxicities or serious adverse events reported.","Company plans to initiate a randomized, double-blind, placebo-controlled Phase 2 study in H2 2022.","Target market: ~170,000 US patients with grade 2/3 RIX; no new treatments approved in >20 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411601,"accession_number":"0001558370-21-015398","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q3 net loss $25.9M ($0.59/sh); cash $143.6M; R&D spend jumps","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.9M ($0.59 loss per share) vs $6.4M ($0.17) YoY; license revenue $6.9M.","R&D expenses surged to $21.6M from $4.6M on clinical trial and manufacturing costs.","Cash and equivalents $143.6M; expects funding into Q2 2023.","Phase 3 Lumeos trial for XLRP screening; AQUAx xerostomia Phase 1 enrollment to complete Q4 2021.","IND planned for AAV-GAD in Parkinson's and Phase 3 pivotal trial for AAV-RPE65 in early 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":16658000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430360,"accession_number":"0001558370-21-011226","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2021-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q2 net loss $20.1M ($0.46/sh); cash runway into Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to shareholders $20.1M ($0.46/sh) vs $25.4M ($0.69/sh) in Q2 2020.","License revenue $5.1M (up from $2.5M); R&D spend $15.2M, G&A $10.4M.","Cash and equivalents $172.6M (down from $194.8M); believes funded into Q2 2023.","Expects to initiate Phase 3 Lumeos trial for XLRP, Phase 3 for AAV-RPE65, and file IND for AAV-GAD in Parkinsons in H2 2021.","Manufacturing facility to support at least six clinical programs in next 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":9711000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-11T23:59:59+00:00|430360"}